Product Description
Ethosuximide is used to control absence seizures (petit mal) (a type of seizure in which there is a very short loss of awareness during which the person may stare straight ahead or blink his eyes and does not respond to others). Ethosuximide is in a class of medications called anticonvulsants. It works by reducing abnormal electrical activity in the brain. (Sourced from: https://medlineplus.gov/druginfo/meds/a682327.html)
Mechanisms of Action: T-Type Calcium Channel Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Czech | Denmark | Egypt | France | Germany | Greece | India | Ireland | Italy | Korea | Lithuania | Luxembourg | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Poland | Romania | Russia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Turkey | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Advicenne Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Abdominal Pain|Irritable Bowel Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IBSET | P2 |
Active, not recruiting |
Irritable Bowel Syndrome|Abdominal Pain |
2019-06-10 |